Mechanobiology-based Innovation
Cardiomyopathies present a huge unmet medical need
Cardiomyopathies are a diverse group of diseases that affect the heart muscle, leading to impaired cardiac structure and function. They are classified into several types, including dilated, hypertrophic, and arrhythmogenic right ventricular cardiomyopathy. The causes of cardiomyopathies can either be genetic or acquired due to factors such as viral infections, chronic high blood pressure, metabolic disorders, or excessive alcohol consumption.
Genetic cardiomyopathies are monogenic heart conditions where disease is predominantly caused by mutations in genes that play a role in cardiac force transmission. 30-50% of cardiomyopathies are believed to have a genetic origin. Mutations in more than 30 genes are known to cause genetic cardiomyopathies, with most mutations inherited autosomal dominantly, meaning that patients have both a normal and a mutant copy of the disease-causing gene. This renders a traditional gene replacement approach infeasible for most of these mutations.
Nuevocor is pioneering a functional approach by leveraging our proprietary PrOSIA platform to elucidate the disease mechanism and develop targeted therapies that treat the root cause of these cardiomyopathies.
Mechanobiology Approach
Nuevocor's strength lies in our innovative PrOSIA mechanobiology platform.
Nuevocor's proprietary PrOSIA mechanobiology platform gives us unprecedented insights into the biomechanical root cause of many genetic and non-genetic cardiomyopathies. This enables us to design novel treatments that target causal biomechanical pathways shared among multiple cardiomyopathies.
With this, we go beyond traditional gene replacement therapy, which treats single gene mutations. We consider ourselves at the forefront of a new generation of mechanobiology companies pioneering such an innovative pathway-specific approach.
